UY34206A - Anticuerpo monoclonal de interleucina-31 - Google Patents

Anticuerpo monoclonal de interleucina-31

Info

Publication number
UY34206A
UY34206A UY0001034206A UY34206A UY34206A UY 34206 A UY34206 A UY 34206A UY 0001034206 A UY0001034206 A UY 0001034206A UY 34206 A UY34206 A UY 34206A UY 34206 A UY34206 A UY 34206A
Authority
UY
Uruguay
Prior art keywords
interleucine
monoclonal antibody
monoclonal
antibody
escanear
Prior art date
Application number
UY0001034206A
Other languages
English (en)
Inventor
Gary F Bammert
dunham Steven
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46704979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34206(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of UY34206A publication Critical patent/UY34206A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Abstract

Se proporciona un anticuerpo aislado que se enlaza de manera específica a por lo menos una de Interleucina-31 (IL-31) canina o IL-31 felina. Dichos anticuerpos pueden estar en la forma de composiciones de diagnóstico y/o vet e r i n a r i a s ú t i l e s para tratar una condición d e p r u r i to y/o de alergia en perros o gatos.
UY0001034206A 2011-07-21 2012-07-20 Anticuerpo monoclonal de interleucina-31 UY34206A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161510268P 2011-07-21 2011-07-21

Publications (1)

Publication Number Publication Date
UY34206A true UY34206A (es) 2013-02-28

Family

ID=46704979

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034206A UY34206A (es) 2011-07-21 2012-07-20 Anticuerpo monoclonal de interleucina-31

Country Status (24)

Country Link
US (6) US8790651B2 (es)
EP (4) EP3842456A1 (es)
JP (1) JP6022563B2 (es)
KR (2) KR101742928B1 (es)
CN (2) CN105504059B (es)
AR (1) AR087281A1 (es)
AU (2) AU2012285432C1 (es)
BR (1) BR112014001407A8 (es)
CA (2) CA2926379A1 (es)
CY (2) CY1119475T1 (es)
DK (1) DK2734549T3 (es)
ES (2) ES2638340T3 (es)
HR (2) HRP20171198T1 (es)
HU (2) HUE034282T2 (es)
LT (2) LT3219729T (es)
ME (1) ME02837B (es)
MX (1) MX349053B (es)
PL (2) PL3219729T3 (es)
PT (2) PT2734549T (es)
RS (2) RS56268B1 (es)
SI (2) SI2734549T1 (es)
UY (1) UY34206A (es)
WO (1) WO2013011407A1 (es)
ZA (1) ZA201400768B (es)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505991C (en) * 2002-11-15 2018-02-27 Genmab A/S Human monoclonal antibodies against cd25
LT3345607T (lt) 2006-12-29 2023-01-10 Ossifi-Mab Llc Kaulų augimo keitimo būdai, skiriant sost arba wise antagonistą ar agonistą
EP3248617A3 (en) * 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
HUE033315T2 (en) * 2010-05-14 2017-11-28 Amgen Inc High concentration antibody preparations
TR201815863T4 (tr) * 2010-11-30 2018-11-21 Chugai Pharmaceutical Co Ltd Sitotoksisiteyi indükleyen terapötik madde.
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN108640996A (zh) * 2012-08-21 2018-10-12 詹森药业有限公司 帕潘立酮的抗体及其用途
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
PT2900263T (pt) * 2012-09-26 2019-07-29 Univ Wuerzburg J Maximilians Anticorpos monoclonais contra o factor de crescimento e diferenciaçao 15 (gdf-15)
WO2014168933A1 (en) * 2013-04-08 2014-10-16 Cytodyn Inc. Felinized antibodies and methods of treating retroviral infections in felines
KR102216088B1 (ko) * 2013-07-25 2021-02-15 싸이톰스 테라퓨틱스, 인크. 다중특이성 항체, 다중특이성 활성화 가능한 항체 및 그의 사용 방법
SG11201603231XA (en) * 2013-11-06 2016-05-30 Janssen Biotech Inc Anti-ccl17 antibodies
US11072647B2 (en) * 2013-12-19 2021-07-27 Onsejo Nacional DE Investigation Cientiticay Tecnica TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
JP6622703B2 (ja) * 2013-12-20 2019-12-18 インターベット インターナショナル ベー． フェー． アンタゴニストの、抗イヌｐｄ−１抗体
RU2769133C2 (ru) * 2013-12-30 2022-03-28 Эпимаб Биотерапьютикс Инк. Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
EP3102939A4 (en) * 2014-02-05 2018-02-28 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
CA2935532A1 (en) * 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
RS59700B1 (sr) * 2014-03-26 2020-01-31 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
EP3157952B1 (en) * 2014-06-20 2021-12-22 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CA2955084C (en) * 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
AU2015344769B2 (en) * 2014-11-12 2020-07-09 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
US10849862B2 (en) * 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
KR20170105558A (ko) 2015-01-30 2017-09-19 각코우호우징 사이타마이카다이가쿠 항 alk2 항체
EP3258959A4 (en) * 2015-02-22 2018-10-17 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
SG11201707593UA (en) * 2015-03-31 2017-10-30 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
KR20240033097A (ko) * 2015-04-14 2024-03-12 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
WO2016167263A1 (ja) 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US11424061B2 (en) * 2015-04-14 2022-08-23 Hanchett Entry Systems, Inc. Solenoid assembly actuation using resonant frequency current controller circuit
CN114652827A (zh) 2015-05-29 2022-06-24 安普希韦纳治疗公司 双特异性cd33和cd3结合蛋白质的使用方法
CN106336459B (zh) * 2015-07-13 2020-12-08 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
CN109608544B (zh) * 2015-11-17 2022-09-16 苏州盛迪亚生物医药有限公司 Pd-l1抗体、其抗原结合片段及其医药用途
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
US20190023786A1 (en) * 2016-01-12 2019-01-24 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
KR20220162800A (ko) * 2016-04-27 2022-12-08 벤치마크 애니멀 헬스 엘티디. 개 아토피성 피부염의 치료
CN107474134B (zh) * 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
WO2017216724A1 (en) * 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
CN117683135A (zh) * 2016-07-14 2024-03-12 百时美施贵宝公司 针对tim3的抗体及其用途
KR20220151021A (ko) 2016-09-01 2022-11-11 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
RU2759334C2 (ru) * 2016-09-21 2021-11-12 Нексткьюр, Инк. Антитела против siglec-15 и способы их применения
MA45801B1 (fr) 2016-11-08 2021-11-30 Regeneron Pharma Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
EP3538558A4 (en) 2016-11-09 2020-07-15 North Carolina State University TREATMENT OF ALLERGIC DISEASES WITH A CHIMERAL PROTEIN
KR20220051269A (ko) * 2016-12-21 2022-04-26 메레오 바이오파마 3 리미티드 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도
WO2018138297A1 (en) * 2017-01-27 2018-08-02 Kymab Limited Anti-opg antibodies
JP7145162B2 (ja) * 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
CN110545844A (zh) * 2017-02-21 2019-12-06 瑞美德生物医药科技有限公司 使用结合细胞毒性t淋巴细胞抗原-4(ctla-4)的抗体的癌症治疗
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3592380A1 (en) * 2017-03-31 2020-01-15 Cellectis New universal chimeric antigen receptor t cells specific for cd22
KR20190140454A (ko) * 2017-04-13 2019-12-19 아두로 바이오테크 홀딩스, 유럽 비.브이. 항-sirp 알파 항체
CR20190541A (es) * 2017-05-26 2020-01-20 Glaxosmithkline Ip Dev Ltd Composiciones biofarmacéuticas y métodos relacionados
WO2018219327A1 (zh) * 2017-06-01 2018-12-06 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
TWI726228B (zh) * 2017-08-09 2021-05-01 國立臺灣大學 Ｃｄ１４拮抗分子用於治療癌症
KR20200037388A (ko) * 2017-08-16 2020-04-08 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, hla-e, ccr4 또는 pd-l1에 결합하는 단백질
MX2020003219A (es) * 2017-09-21 2020-07-20 Imcheck Therapeutics Sas Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
WO2019086694A1 (en) 2017-11-06 2019-05-09 Geert Mudde Il31 antigen and vaccine
WO2019104157A1 (en) * 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
CN111448208B (zh) * 2017-12-11 2024-02-27 Ubi Ip控股公司 用于治疗和/或预防异位性皮肤炎的il-31肽免疫原及其剂型
CN111542540A (zh) 2017-12-18 2020-08-14 瑞泽恩制药公司 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
EP3749346A4 (en) 2018-02-08 2021-12-15 Dragonfly Therapeutics, Inc. VARIABLE DOMAINS OF ANTIBODIES TARGETING THE NKG2D RECEIVER
WO2019155427A1 (en) * 2018-02-09 2019-08-15 Nestlé Skin Health Sa Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
WO2019177138A1 (ja) * 2018-03-16 2019-09-19 国立大学法人滋賀医科大学 異常ｔｄｐ－４３を分解除去する抗体断片
KR20230145511A (ko) 2018-03-16 2023-10-17 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체
KR20200142010A (ko) 2018-03-16 2020-12-21 조에티스 서비시즈 엘엘씨 인터루킨-31에 대한 펩티드 백신
KR20200141461A (ko) * 2018-04-06 2020-12-18 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 작용제 항체를 사용한 치료 방법
CN112105629A (zh) * 2018-05-09 2020-12-18 古德T细胞有限公司 调节性t细胞表面抗原的表位以及与其特异性结合的抗体
US20210214456A1 (en) * 2018-06-13 2021-07-15 Kymab Limited Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
TWI822815B (zh) * 2018-07-14 2023-11-21 財團法人生物技術開發中心 抗-人類ｐｄ-ｌ１之抗體及其用途
CA3109905A1 (en) * 2018-08-20 2020-02-27 Pfizer Inc. Anti-gdf15 antibodies, compositions and methods of use
CA3120474A1 (en) * 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
BR112021012513A2 (pt) 2019-01-03 2021-09-14 Invetx Inc. Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso
AU2020248645A1 (en) * 2019-03-27 2021-10-28 Tigatx, Inc. Engineered IgA antibodies and methods of use
EP3962936A1 (en) * 2019-05-03 2022-03-09 Singapore Health Services Pte. Ltd. Treatment and prevention of metabolic diseases
CN110283246A (zh) * 2019-06-20 2019-09-27 长春西诺生物科技有限公司 一种抗猫细小病毒的猫源化基因工程抗体
US11890353B2 (en) * 2019-10-15 2024-02-06 Northwestern University Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
BR112022011669A2 (pt) 2019-12-20 2022-09-06 Intervet Int Bv Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica
MX2022007677A (es) 2019-12-20 2022-07-19 Intervet Int Bv Anticuerpos para receptor alfa de interleucina-4 canino.
WO2021207242A2 (en) * 2020-04-07 2021-10-14 Fred Hutchinson Cancer Research Center Anti-mesothelin antigen-binding molecules and uses thereof
JP2023522029A (ja) 2020-04-17 2023-05-26 ゾエティス・サービシーズ・エルエルシー イヌ科動物抗体バリアント
CN115667300A (zh) 2020-04-17 2023-01-31 硕腾服务有限责任公司 猫抗体变异体
MX2022013176A (es) * 2020-04-24 2022-11-30 Millennium Pharm Inc Anticuerpos anti cumulo de diferenciacion 19 (cd19) y sus usos.
WO2021223719A1 (zh) * 2020-05-08 2021-11-11 亘喜生物科技（上海）有限公司 一种抗cd19抗体的抗体及其制备和应用
JP2023526225A (ja) 2020-05-11 2023-06-21 インベテックス インコーポレイテッド 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法
CN115768516A (zh) * 2020-05-22 2023-03-07 瑞泽恩制药公司 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
BR112022027028A2 (pt) 2020-07-10 2023-03-07 Invetx Inc Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso
MX2023001490A (es) * 2020-08-05 2023-04-27 Synthekine Inc Moleculas de union a il27r\03b1 y metodos de uso.
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
FR3113458B1 (fr) 2020-08-21 2022-10-14 Purally Composition comprenant au moins un flavonoide glycosyle et son utilisation en cosmetique ou dermatologie
KR20230052963A (ko) * 2020-08-21 2023-04-20 젠자임 코포레이션 Fgfr3 항체 및 사용 방법
TW202229337A (zh) 2020-09-28 2022-08-01 美商碩騰服務公司 犬抗體變異體
CN116457369A (zh) 2020-09-29 2023-07-18 硕腾服务有限责任公司 猫抗体变体
WO2022079139A1 (en) 2020-10-15 2022-04-21 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
TW202221039A (zh) 2020-10-19 2022-06-01 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
WO2022094009A1 (en) * 2020-10-30 2022-05-05 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single domain antibodies to sars-cov-2 nucleocapsid protein
CN116981691A (zh) * 2020-11-23 2023-10-31 斯克奥特比奥股份有限公司 抗原结合分子及其用途
CA3202074A1 (en) * 2020-12-18 2022-06-23 Zoetis Services Llc Mutations in feline antibody constant regions
WO2022165067A2 (en) 2021-01-28 2022-08-04 Zoetis Services Llc Mutations in canine antibody constant regions
EP4284831A1 (en) 2021-01-29 2023-12-06 Bayer Animal Health GmbH Vaccine composition for breaking self-tolerance
WO2022178201A1 (en) 2021-02-22 2022-08-25 Zoetis Services Llc Horse il-31 induced pruritus model
JP2024512574A (ja) * 2021-03-22 2024-03-19 ノビミューン エスアー Ｃｄ４７およびｐｄ－ｌ１を標的とする二重特異性抗体ならびにその使用方法
US20220348659A1 (en) * 2021-03-24 2022-11-03 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
TW202308691A (zh) * 2021-04-23 2023-03-01 瑞典商阿斯特捷利康公司 狼瘡性腎炎之治療
CA3227816A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Fusion proteins for treating atopic dermatitis
WO2023111128A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha ii
WO2023152486A1 (en) 2022-02-09 2023-08-17 Petmedix Ltd Therapeutic antibodies
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
WO2024057096A1 (en) 2022-09-14 2024-03-21 Ceva Sante Animale Treatment of atopic dermatitis using self-replicating rna expressing il-31
CN115505575B (zh) * 2022-11-16 2023-03-24 中国科学院天津工业生物技术研究所 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
AU4102099A (en) * 1998-05-29 1999-12-13 Heska Corporation Canine Interleukin -4 Proteins, Nucleic Acid Molecules, and Uses Thereof
AU767172B2 (en) 1999-03-18 2003-11-06 Merck Patent Gmbh Protein for blocking platelet adhesion
EP1130098A3 (en) 2000-02-29 2003-09-10 Pfizer Products Inc. Mammalian osteoregulins
US6989145B2 (en) 2000-03-03 2006-01-24 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody and antibody fragment
KR100419555B1 (ko) 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US6818444B2 (en) * 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
JP2005514063A (ja) 2001-12-21 2005-05-19 イデックス ラボラトリーズ インコーポレイテッド イヌ免疫グロブリン可変ドメイン、イヌ化抗体、ならびにそれらを作製および使用する方法
ES2351678T3 (es) 2002-01-18 2011-02-09 Zymogenetics, Inc. Ligando de citocina para el tratamiento de asma e hiper-sensibilidad de las vías respiratorias .
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
EP1629013B1 (en) * 2003-05-31 2018-01-24 Amgen Research (Munich) GmbH Pharmaceutical composition comprising a bispecific antibody specific for epcam
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1848737B1 (en) 2005-01-28 2016-05-18 ZymoGenetics, Inc. Homogeneous preparations of il-31
WO2008021976A2 (en) 2006-08-09 2008-02-21 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
CA2595939C (en) 2005-02-14 2014-08-19 Zymogenetics Inc. Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists
AU2006214404B2 (en) 2005-02-14 2012-03-08 Bristol-Myers Squibb Company Methods of treating skin disorders using an IL-31RA antagonist
JP2008535823A (ja) * 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
EP1891111A1 (en) 2005-05-06 2008-02-27 ZymoGenetics, Inc. Il-31 monoclonal antibodies and methods of use
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
EP2749571A3 (en) 2006-01-10 2014-08-13 ZymoGenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists
BRPI0715660B8 (pt) * 2006-09-01 2021-05-25 Zymogenetics Inc anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
EP2829551B1 (en) 2006-10-19 2017-12-13 CSL Limited High affinity antibody antagonists of interleukin-13 receptor alpha 1
LT2796466T (lt) * 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
ME01269B (me) * 2008-08-20 2013-06-20 Zoetis Services Llc Jedinjenja pirolo (2,3-d) pirimidina
WO2010027488A2 (en) 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
WO2011065935A1 (en) 2009-11-24 2011-06-03 Cornell University Methods for monoclonal antibody production
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
EP2488658A4 (en) 2009-10-15 2013-06-19 Abbvie Inc IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
NZ724971A (en) 2010-02-24 2019-06-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
DK2644698T3 (en) * 2010-11-17 2018-01-22 Chugai Pharmaceutical Co Ltd MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATIVE FUNCTION TO BLOOD COAGULATION FACTOR FUNCTION VIII
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN103717613A (zh) 2011-07-22 2014-04-09 葛兰素史密丝克莱恩生物有限公司 Prame纯化
KR20230145511A (ko) * 2018-03-16 2023-10-17 조에티스 서비시즈 엘엘씨 수의학적 용도를 위한 인터류킨-31 단클론성 항체

Also Published As

Publication number Publication date
AU2012285432B2 (en) 2016-06-16
WO2013011407A1 (en) 2013-01-24
CA2842475A1 (en) 2013-01-24
SI3219729T1 (sl) 2020-11-30
US20140315251A1 (en) 2014-10-23
EP3653645A1 (en) 2020-05-20
NZ620031A (en) 2016-03-31
PL2734549T3 (pl) 2017-11-30
RS60924B1 (sr) 2020-11-30
CN105504059B (zh) 2020-08-11
MX2014000803A (es) 2014-03-31
US10421807B2 (en) 2019-09-24
EP3842456A1 (en) 2021-06-30
US20190092854A1 (en) 2019-03-28
CA2842475C (en) 2018-01-02
ES2638340T3 (es) 2017-10-19
AU2012285432C1 (en) 2016-12-22
CY1119475T1 (el) 2018-03-07
US20190389944A1 (en) 2019-12-26
CN103890009B (zh) 2017-02-15
JP6022563B2 (ja) 2016-11-09
ES2827231T3 (es) 2021-05-20
ZA201400768B (en) 2015-12-23
MX349053B (es) 2017-07-06
BR112014001407A2 (pt) 2017-03-01
US20190359702A1 (en) 2019-11-28
ME02837B (me) 2018-01-20
AU2012285432A1 (en) 2014-01-30
CN105504059A (zh) 2016-04-20
EP2734549B1 (en) 2017-05-24
KR20140041858A (ko) 2014-04-04
RS56268B1 (sr) 2017-11-30
AU2016203590B2 (en) 2017-12-21
KR101613024B1 (ko) 2016-04-18
HUE051068T2 (hu) 2021-01-28
CA2926379A1 (en) 2013-01-24
PT2734549T (pt) 2017-08-29
HRP20201634T1 (hr) 2020-12-25
SI2734549T1 (sl) 2017-10-30
RU2014101250A (ru) 2015-08-27
KR101742928B1 (ko) 2017-06-01
LT3219729T (lt) 2020-11-25
EP3219729B1 (en) 2020-09-09
CY1123791T1 (el) 2022-03-24
BR112014001407A8 (pt) 2022-11-08
US10526405B2 (en) 2020-01-07
US20130022616A1 (en) 2013-01-24
DK2734549T3 (en) 2017-09-11
KR20160028488A (ko) 2016-03-11
HRP20171198T1 (hr) 2017-10-20
CN103890009A (zh) 2014-06-25
JP2014529295A (ja) 2014-11-06
US8790651B2 (en) 2014-07-29
PL3219729T3 (pl) 2021-01-25
PT3219729T (pt) 2020-10-23
US20140286958A1 (en) 2014-09-25
US9206253B2 (en) 2015-12-08
AU2016203590A1 (en) 2016-06-16
AR087281A1 (es) 2014-03-12
HUE034282T2 (en) 2018-02-28
EP2734549A1 (en) 2014-05-28
EP3219729A1 (en) 2017-09-20
LT2734549T (lt) 2017-09-11

Similar Documents

Publication Publication Date Title
UY34206A (es) Anticuerpo monoclonal de interleucina-31
UY34456A (es) Anticuerpos anti-il-36r
CO7020912A2 (es) Inhibidores de bromodominios
CO6811812A2 (es) Anticuerpo anti-b7-h3
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
CR20140024A (es) Compuestos inhibidores de metaloenzimas
UY34836A (es) Nuevo organismos
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34654A (es) Inhibidores de la beta-secretasa
CR20140127A (es) Anticuerpo anti-abtcr
UY34119A (es) Montaje machihembrado de fijación
UY34074A (es) Composición oftálmica de olopatadina altamente concentrada
BR112014003027A2 (pt) formulação herbicida melhorada
BR112014026634A2 (pt) direcionador
UY4153Q (es) Batería
UY34158A (es) Composicion herbicida
BR112014027219A2 (pt) método
UY34286A (es) Diagnóstico de vacuna mejorado
CO7111295A2 (es) Anticuerpo anti-rob04
CO6841994A2 (es) Anticuerpos
UY34483A (es) Polipeptido
UY4152Q (es) Batería
CL2012001192S1 (es) Botella.
FR2981207B1 (fr) Source multi-faisceaux

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20220527